Iomab-ACT

Actinium Pharmaceuticals has enrolled the first patient in a pioneering trial evaluating Iomab-ACT as a targeted radiotherapy conditioning agent with commercial CAR-T therapy, with initial data expected in late 2025.

Actinium Pharmaceuticals is set to release topline data from its pivotal Phase III SIERRA trial of Iomab-B for relapsed/refractory acute myeloid leukemia (AML) in Q4 2022.

Actinium Pharmaceuticals aligned with the FDA on a Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory AML, aiming for optimized dosing and reduced trial timelines.

The SIERRA trial showed that Iomab-B led to a significantly higher durable complete remission rate (17.1%) compared to conventional care (0%) in older patients with relapsed/refractory AML.

The Phase 3 SIERRA trial demonstrated that Iomab-B achieved a statistically significant durable Complete Remission (dCR) rate of 22% compared to 0% in the control arm for relapsed/refractory AML patients.